Next Article in Journal
Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination Strategy
Next Article in Special Issue
Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review
Previous Article in Journal
Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation
Previous Article in Special Issue
A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 3
10.3390/cancers17030393
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas

by
Jules P. J. Douwes
1,*,
Ronald van Eijk
2,
Sybren L. N. Maas
2,3,
Jeroen C. Jansen
1,
Emmelien Aten
4 and
Erik F. Hensen
1
1
Department of Otorhinolaryngology—Head and Neck Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
2
Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
3
Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 CN Rotterdam, The Netherlands
4
Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(3), 393; https://doi.org/10.3390/cancers17030393
Submission received: 3 December 2024 / Revised: 11 January 2025 / Accepted: 22 January 2025 / Published: 24 January 2025
(This article belongs to the Special Issue Neurofibromatosis)
Browse Figures
Review Reports Versions Notes

Simple Summary

Vestibular schwannomas are tumors that occur on the nerve responsible for hearing and balance, the vestibulocochlear nerve. These benign tumors may appear on one side (unilateral) or both sides (bilateral), with bilateral cases often linked to a condition called NF2-related schwannomatosis. This study explored the genetic causes of vestibular schwannomas in three groups: patients with NF2, younger patients with a unilateral tumor, and older patients with a unilateral tumor. By analyzing DNA from the tumors and blood, we aimed to understand the genetic mutations that drive tumor development and how the genetics differed between the three groups. In all patients, it was found that one gene, NF2, played a major role in the development of vestibular schwannomas. However, there were also differences found in the types of genetic mutations and mechanisms involved, offering new insights into how these tumors form and progress.

Abstract

Background: Unilateral (uVS) and bilateral vestibular schwannoma (bVS) are distinct disease types, yet share tumorigenic features. This study examined causative genetic alterations in three groups: patients with NF2-related schwannomatosis (NF2), young patients with uVS (≤30 years), and older patients with uVS (≥40 years). Methods: Lymphocyte and vestibular schwannoma DNA was genetically analyzed. Outcomes included gene involvement, pathogenicity classification, variant type, effect, and location, and loss of heterozygosity (LOH) of chromosome 22. Results: Among 93 patients, 17% had NF2, 39% were ≤30 years with uVS, and 44% were ≥40 years with uVS. In all patients with NF2 (100%), two or more hits were detected in the tumor DNA, whereas patients with uVS had a slightly lower detection rate (89–98%). NF2-related tumors had a higher frequency of nucleotide variants (76%), while LOH events were more common in uVS (64–69%). Variants were mostly identified in NF2, with nonsense variants over-represented in patients with NF2 (38%) and frameshift variants more prevalent in uVS (44–51%). Conclusions: Biallelic NF2 inactivation primarily drives vestibular schwannoma tumorigenesis. In patients with NF2, two pathogenic NF2 variants or one NF2 variant with LOH are common, whereas patients with uVS often exhibit one NF2 variant with LOH. Additionally, variant types differ between patient groups.

1. Introduction

Vestibular schwannomas (VSs) are benign nerve sheath tumors affecting the vestibular branch of the eighth (vestibulocochlear) cranial nerve. Globally, the annual incidence of vestibular schwannomas has been estimated at 1 in 64,000 to 92,000 people, resulting in a lifetime risk of 1 in every 1000 individuals [1,2,3]. Common symptoms that vestibular schwannomas present with are hearing loss, tinnitus, and vestibular complaints [4,5]. These may be impacted by determinants such as tumor size, intrameatal and/or extrameatal tumor location, cystic elements, and involvement of the cochlea and brainstem [6]. Management options include active surveillance, surgical resection, and radiotherapy [7]. Therapeutic interventions achieve overall adequate tumor control; however, vestibular schwannomas are associated with morbidity and a reduced quality of life because of the sequalae of the disease itself and/or the interventions performed [8,9,10].
Sporadic vestibular schwannomas typically arise unilaterally (uVSs). Bilateral vestibular schwannomas (bVSs), in contrast, are the hallmark lesion for NF2-related schwannomatosis (NF2) [11], a tumor syndrome predisposing one to multiple central nervous system tumors, including schwannomas, meningiomas, and ependymomas [11,12]. In the majority of cases, vestibular schwannoma is unilateral and solitary, but in 5% to 7%, it is associated with NF2 [1,13]. In contrast to uVS, NF2-related bVS may develop at a younger age, show a higher tumor progression rate, and respond less favorably to standard treatment options. As a result, patients with NF2 experience a higher morbidity, a higher mortality, and a more substantial decline in their quality of life [14,15,16]. The clinical severity of NF2, however, is highly variable. According to classical phenotype models, NF2 can present as a more severe (Wishart) phenotype with an early age of onset and a milder (Feiling–Gardner) phenotype with a later onset [17]. More detailed genotype–phenotype correlations have been proposed to predict the clinical severity of NF [16,18,19]. Other molecular measures, such as dysregulated cellular pathways and tumor microenvironment, are also coming to the forefront to provide greater prognostic insight [20,21,22].
The tumorigenesis of both uVS and bVS is hypothesized to be the result of a two-hit mutational mechanism, most frequently caused by inactivation of the neurofibromatosis type 2 (NF2) tumor suppressor gene, either by mutation of the NF2 or loss of chromosome 22q (LOH) [23,24,25,26]. In the majority of tumors, a pathogenic nucleotide variant in NF2 is detected together with the loss of the NF2 wildtype copy of chromosome 22q. In NF2-related schwannomatosis, constitutional frameshift and nonsense (truncating) variants are linked to an aggressive phenotype originating at an adolescent age. Missense, in-frame, and silent variants have been associated with a milder phenotype and greater life expectancy, while splice-site and (multiple) exon-deleting variants result in a more variable clinical severity [16,18,27]. Vestibular schwannomas have also been associated with variants in several other genes, such as CDC27, CDKN2A, LZTR1, MDM2, PRKAR1A, SMARCB1, TSC1, and TSC2 [20,24,26,27,28,29,30,31,32,33,34,35].
Although they are distinct disease types, there is both a clinical and genetic overlap between patients with uVS and patients with NF2-related bVS. It seems logical to suggest that young patients with NF2 develop uVS before they develop bVS, while patients under 30 years old presenting with uVS have a greater risk of developing bVS at a later point in life [36,37]. Testing for NF2 is therefore imperative in young patients less than 30 years of age with schwannomas of any location. It has also been suggested that uVS can be a milder phenotypical expression of NF2, as mosaicism rates of de novo NF2 have been found to be 60%, substantially higher than previously expected [19,38]. At the same time, true uVS typically develops after the age of 40 years [1,39]. Therefore, differences in the phenotype of patients with NF2 and patients with uVS, but also within-group differences for uVS, may be the result of distinct mutational mechanisms [40].
The aim of this study was to evaluate the causative genetic alterations of vestibular schwannomas in different patient groups, i.e., patients with confirmed NF2, young patients with uVS (≤30 years), and older patients with uVS (≥40 years).

2. Materials and Methods

2.1. Participants and Study Design

The present study included patients that were surgically treated for a vestibular schwannoma at the Leiden University Medical Center (LUMC) in The Netherlands, a tertiary skull base and NF2 referral center, between 1 December 1997 and 31 December 2023. The inclusion criteria comprised patients ≥ 18 years old with NF2-related or unilateral vestibular schwannoma and for whom frozen or fixated paraffine tumor material was available for retrospective genetic analysis. The diagnosis of NF2 was confirmed using the updated clinical and radiologic criteria [12]. The exclusion criteria comprised insufficient demographic or clinical data, tumor material with a lack of qualitative or quantitative DNA for genetic analysis, and other schwannomatosis-related disease types.
Following ethical approval and informed consent, electronic patient files were retrospectively examined for demographic, clinical, and genetic characteristics. Tumor specimens for variant analysis were collected from the Department of Pathology (LUMC), stored for long-term safekeeping in accordance with national guidelines. A secured online database was set up for the collection and storage of data. The study protocol was conducted in compliance with the ethical standard of The Declaration of Helsinki (2013).

2.2. Demographics and Clinical Assessment

The demographics included vital status, sex, age at the time of diagnosis, and age at the time of surgical intervention. For the present analysis, patients were divided into three groups: patients with clinically or genetically confirmed diagnosis of NF2-related schwannomatosis, patients ≤ 30 years old when diagnosed with uVS, and patients ≥ 40 years old when diagnosed with uVS. Clinical outcomes of interest included tumor characteristics, treatment history, family history of NF2 or uVS, and genetic germline diagnostics (in the case of NF2 or individuals at risk of NF2 [41]).

2.3. DNA Extraction and Analysis

Germline DNA was extracted from peripheral blood lymphocytes, and vestibular schwannoma DNA was extracted from micro-dissected frozen or paraffine tumor specimens, using standard diagnostic procedures. In some cases, a genetic analysis had already been performed on lymphocyte DNA and/or tumor specimens prior to this study at the discretion of the treating multidisciplinary team or in compliance with patient preferences [42].
Since 2017, next-generation sequencing (NGS) has been used as the golden standard for detecting pathogenic variants in clinical settings [43]. Prior to that, direct Sanger sequencing and multiple ligation-dependent probe amplification (MLPA) were employed. Although NGS is favored over Sanger sequencing, we included all individuals that had received germline and/or tumor analysis to deal with sample size constraints. All the included samples were sequenced and analyzed according to a globally recognized standard for quality management and handled according to medical ethical guidelines described in the Code Proper Secondary Use of Human Tissue established by the Dutch Federation of Medical Sciences [44].
The LUMC Department of Pathology (section Molecular Diagnostics) designed an Ion-Torrent-based NGS Ampliseq gene panel (Thermo Scientific, Waltham, MA, USA), named Rare Cancer PaneL (RCPL) [45]. The RCPL sequences genes and hotspot regions in rare tumors that frequently express distinct mutational profiles. For vestibular schwannomas, the RCPL includes, among others, the following relevant genes: CDC27, CDKN2A, LZTR1, MDM2/CDK4, NF2, PRKAR1A, SMARCB1, SMARCE1, TSC1, and TSC2. Additionally, LOH were assessed for chromosome 22. The sequencing criteria have been described in more detail in the RCPL guideline [45].
Outcomes of interest included the affected gene, pathogenicity classification according to the American College of Medical Genetics and Genomic [46], variant type, variant effect, location of the variants according to predetermined NF2 gene domains (exon 1, exon 2–7, exon 8–13, and exon 14–17) [16,18], and presence of LOH. If applicable, a genetic severity score was established [18].

2.4. Statistics

For the statistical analyses, IBM SPSS Statistics for Windows (version 27.0. Armond, NY, USA: IBM Corp) was used. Descriptive statistics were used to describe patient characteristics. Non-normally distributed data were reported using median, range, frequency count, and percentages. Missing, unused, and incorrect data were documented and adjusted for during data collection and study analysis.

3. Results

3.1. Patient Characteristics

Ninety-three patients were included. Of these, 16 patients (17%) were diagnosed with NF2, 36 patients (39%) were ≤30 years old with uVS, and 41 patients (44%) were ≥40 years old with uVS (Table 1). The median age at diagnosis was 33.7 years (12.6–61.9) for NF2, 27.1 (16.7–30.6) for young patients with uVS, and 55.5 (40.0–79.5) for older patients with uVS. Fifteen patients with NF2 (94%) presented with bilateral vestibular schwannomas. Three patients with NF2 (19%) passed away after being diagnosed, and no deaths were recorded among the patients with uVS.

3.2. Germline Analysis

Germline sequencing of NF2 was performed in twelve patients with NF2 (75%) prior to this study. Variant analysis was primarily performed with a combination of Sanger sequencing and MLPA (8/12, 67%), followed by Sanger sequencing alone (2/12, 17%) and NGS (1/12, 8%). For one case, the sequencing technique was unknown.
In five patients with NF2 (42%), a pathogenic germline variant was detected. Their median age at presentation was 24.3 years (12.5–30.6). Patient 7 had a large deletion of 19 genes on chromosome 22, including exon 1 of the NF2 gene. No pathogenic variants were detected in LZTR1 and SMARCB1. The other four patients had different nucleotide variants of NF2, all classified as likely pathogenic (Human Genome Variation Society Nomenclature class 4) [47]. The molecular details are described in Table 2.
Twenty-three young patients with uVS (66%) underwent germline NF2 screening [36]. We deployed Sanger sequencing with MLPA in fifteen cases (65%), NGS in seven cases (30%), and a sequencing technique of unknown origin in a single case (4%). All patients (100%) were tested for NF2, while fourteen patients (61%) were additionally tested for LZTR1 and five (22%) for SMARCB1 alterations. One patient (4%) harbored an LZTR1 variant (NM_006767.3 (exon 13): c.1433G > A, p.Arg478Gln), yet pathogenicity was unknown (class 3, variant of unknow significance (VUS)). No other variants were detected.

3.3. Tumor Analysis

Tumor samples were primarily analyzed using NGS (NF2: 94%; uVS ≤ 30 years: 92%; and uVS ≥ 40 years: 100%), specifically with the RCPL (NF2: 89%; uVS ≤ 30 years: 94%; and uVS ≥ 40 years: 100%). The remaining samples were sequenced using Sanger sequencing and MLPA.
In all patients with NF2 (100%), two or more hits were detected in the tumor DNA. The detection rate was marginally lower for patients with uVS: at least 1 hit in 32 out of 36 tumors (89%) among young patients with uVS and 40 out of 41 tumors (98%) in older patients with uVS. Patients with NF2-related schwannomatosis harbored an even distribution of tumor samples with either two distinct nucleotide variants or one variant as the presumed first hit and the LOH of chromosome 22 as the second hit. The majority of patients with uVS possessed the latter (Figure 1).
Two patients with NF2 harbored three hits: a germline NF2 variant, a second hit in NF2, and a third SMARCB1 VUS or LOH of chromosome 22, respectively. Among the patients with uVS, three individuals aged ≤30 years and four aged ≥40 years showed a three- or four-hit mechanism in the tumor sample. A relatively high number of nucleotide variants were found in the NF2-related samples, whereas the samples from patients with uVS showed more LOH events (Figure 2). The screening details are available online in the Supplementary Materials.
Nucleotide variants were primarily identified in NF2 in comparison to other genes (Table 3). Tumors from younger patients with uVS harbored the greatest diversity of variants, namely in NF2 (n = 40; 85%), SMARCB1 (n = 3; 6%), TSC1 (n = 2; 4%), LZTR1 (n = 1; 2%), and NF1 (n = 1; 2%). In the NF2 gene, a substitution was predominant in patients with NF2 compared to a frameshift deletion in older patients with uVS. Nonsense variants were most frequently identified in NF2-related tumors, while frameshift variants predominated in patients with uVS.
All five patients with NF2 that had an identifiable germline variant also had a second NF2-related pathogenic hit in the tumor (Table 4). In two out of the five tumors (40%), a truncation was identified.

3.4. Age Differences in NF2

An additional subgroup analysis was performed on the NF2 cohort, based on their age of diagnosis in relation to the group’s median age. Young patients with NF2 (<33.7 years) had a more severe clinical phenotype compared to older patients with NF2 (>33.7 years) with respect to their vital status (deceased, % = 38 vs. 0), the presence of meningiomas (patients, % = 100 vs. 38), and the total tumor load (tumor count, median = 15 vs. 5).
The genetic analysis showed that younger patients with NF2 were more likely to harbor a nucleotide variant in NF2 as the second hit (patients, % = 63 vs. 38), had a higher variant pathogenicity (classification, mean = 4.1 vs. 3.8), and carried more truncating variants in the tumor (variants, % = 73 vs. 50). On the other hand, LOH was less prevalent in the younger NF2 subgroup (patients, % = 50 vs. 71).

3.5. Sequencing Statistics

An average sequencing coverage of 94.6% (range 92.3–98.9%) for the coding sequences of NF2, LZTR1, and SMARCB1 was achieved. Targeted bases were sequenced at least 150 times with an average of >1000 reads. Further details are provided in the RCPL source file [45].

4. Discussion

In the present study, causative genetic alterations of vestibular schwannomas were investigated from patients with NF2, young patients with uVS (age ≤ 30 years), and older patients with uVS (age ≥ 40 years). All patients showed pathogenic gene variants located in NF2, underlining its central role as a driver in the pathogenesis of NF2-related and sporadic vestibular schwannomas [24,27].
However, our results also show genetic differences between the study groups. Patients with NF2-related schwannomatosis had an even distribution of samples with either two distinct NF2 variants or one NF2 variant and LOH of chromosome 22 (44%), whereas patients with uVS predominantly possessed one NF2 variant with LOH (53–59%). The frequency of LOH also varied across study groups. Previously reported rates in patients with uVS ranged between 53% and 75% [24,27,31,37,48]. In patients with NF2, a slightly lower range of 45% to 67% was described [26,27,49]. Here, we detected similar rates of LOH: 62% for NF2-related tumors, 68% for young patients with uVS, and up to 73% in older patients with uVS. These findings support the hypothesis that biallelic inactivation of the NF2 gene is required for the tumorigenesis of vestibular schwannoma, yet they also point out possible different mutational pathways observed in patients with NF2 and patients with uVS [24,25,26,31]. One possible explanation may be the unique timing of mutational events, as patients with NF2 already harbor pathogenic NF2 variants during the embryonic stage. However, other explanations such as intronic variants, copy-neutral LOH, or technical limitations of panel-based NGS should also be considered.
In total, nucleotide variants constituted 76% of the mutational hits in patients with NF2, 69% in younger patients with uVS, and 64% in older patients with uVS. As with most tumor-suppressor genes, most mutations in NF2 were predicted to truncate (by nonsense or frameshift) or shorten (by incorrect splicing) the protein product. Truncating variations were most prevalent across all three study groups, yet a difference was observed in the truncation type. Nonsense variants were predominant over frameshift variants in patients with NF2, in line with previous studies on patients with NF2 [19,50]. On the other hand, frameshift variants were more prevalent in patients with uVS and the ratio of frameshift to nonsense variants substantially increased with an older age in patients with uVS [26,37,48]. This is in agreement with the hypothesis that age-related increase in mutagenesis and decreased potential for DNA repair lead to an altered mutational pattern [37,41,48]. Splice-site NF2 variants are the second most common mutational hit after truncation. This was also visible in our data. Interestingly, substantial phenotypic variability can be observed between splice-site variants [16,18,51,52]. Our sample size was too small to test for such phenotypic differences. Missense variants are less common, but occur somewhat more frequently in NF2-related tumors than their unilateral counterpart [53,54].
The exon location of pathogenic variants alone has also been linked to specific NF2 genotype–phenotypes, with variants detected towards the 5′ end of NF2 being associated with a more severe phenotype [18]. In uVS, a similar trend towards the 5′ end has been observed [55]. In all three our study groups, the majority of patients harbored nucleotide variants of NF2 towards the 5′ end. A correlation with their clinical phenotype was beyond the scope of this research.
In a minority of tumors found across all patient subgroups, the pathogenic gene variants in NF2 were accompanied by variants in other genes, such as LZTR1 and SMARCB1, two candidate genes for an alternative diagnosis of 22q-related schwannomatosis (SWN), and tumor suppressor gene TSC1, which may function as a co-factor in tumorigenesis. While this highlights the genetic heterogeneity in the tumorigenesis of vestibular schwannomas [33,35], the detection rates of genetic variants in genes other than NF2 remain low and vary across studies [33,35,48,50,56].
This study has several limitations. All patients in the present study received surgery, thus introducing selection bias towards a more severe phenotype which required surgical intervention. Additionally, the sample size of the groups of patients with NF2 was relatively small, inherent to the rarity of NF2. We performed statistical comparisons for all variables possible, yet, due to a lack of power, we were not able to demonstrate statistically significant results. Furthermore, the reliance on archival tumor samples (the oldest sample dating back to 1997) for genetic analysis may have introduced potential biases related to sample quality, tissue preservation methods, and variations in sequencing techniques over time. Lastly, variability in sequencing techniques across patients could have introduced underestimations or inconsistencies in variant detection and interpretation.
Despite these limitations, several strengths can also be identified. First, the inclusion of three distinct patient groups—patients with NF2, younger patients with uVS (≤30 years), and older patients with uVS (≥40 years)—provided a valuable evaluation of vestibular schwannomas across different age groups and disease subtypes. Second, the incorporation of both germline and tumor DNA analysis provided insights into both hereditary and somatic genetic events contributing to vestibular schwannoma tumorigenesis.
NF2-related schwannomatosis is a disease characterized by considerable clinical variation, with patients who present with progressive tumors at a young age and others who present with limited, slowly progressive disease at an older age. This is highlighted by the genetic differences found in the present young and old NF2 subgroups. In the present study, no young patient with uVS harbored a germline NF2 variant. The mutational hits and number of mutational events appeared to be more similar to older patients with uVS than to patients with NF2. Therefore, the expectation is that few young patients with uVS actually harbored NF2-related schwannomatosis. A follow-up analysis with age-matched patients with uVS could provide further insights into the unique genetic characteristics of vestibular schwannomas across disease subtypes and severities, while it may also help predict the risk of developing bVS at a later point in life.

5. Conclusions

Our study contributes to a better understanding of the genetic alterations in vestibular schwannomas across different disease subtypes and age groups. In all three study groups, biallelic inactivation of the NF2 gene was the main cause of vestibular schwannoma tumorigenesis. However, in patients with NF2, we found an even distribution of either pathogenic gene variants in both NF2 copies or one pathogenic variant together with the LOH of chromosome 22. Meanwhile, in patients with uVS, we most frequently observed a single pathogenic NF2 variant in combination with LOH. In addition, truncating variations were the most prevalent across subgroups, yet a difference was observed in the truncation type: nonsense variants were over-represented in patients with NF2, whereas frameshift variants were more prevalent in uVS.

Supplementary Materials

The following supporting information can be downloaded at www.mdpi.com/article/10.3390/cancers17030393/s1, Table S1: Patient characteristics and genetics.

Author Contributions

Conceptualization, J.P.J.D., E.A. and E.F.H.; methodology, J.P.J.D., R.v.E., S.L.N.M., E.A. and E.F.H.; validation, J.P.J.D. and R.v.E.; formal analysis, J.P.J.D.; investigation, J.P.J.D. and R.v.E.; resources, J.P.J.D., R.v.E., S.L.N.M., J.C.J., E.A. and E.F.H.; data curation, J.P.J.D. and R.v.E.; writing—original draft preparation, J.P.J.D.; writing—review and editing, J.P.J.D., R.v.E., S.L.N.M., J.C.J., E.A. and E.F.H.; visualization, J.P.J.D.; supervision, R.v.E., J.C.J., E.A. and E.F.H.; and project administration, J.P.J.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Leiden University Medical Center (nWMO-div3, ref. 23-3032, 24 April 2023).

Informed Consent Statement

Informed consent was obtained from all the subjects involved in this study.

Data Availability Statement

The original contributions presented in this study are included in the Supplementary Materials. Further inquiries can be directed to the corresponding authors.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Evans, D.G.; Moran, A.; King, A.; Saeed, S.; Gurusinghe, N.; Ramsden, R. Incidence of Vestibular Schwannoma and Neurofibromatosis 2 in the North West of England over a 10-year Period: Higher Incidence than Previously Thought. Otol. Neurotol. 2005, 26, 93–97. [Google Scholar] [CrossRef] [PubMed]
  2. Kleijwegt, M.; Ho, V.; Visser, O.; Godefroy, W.; van der Mey, A. Real Incidence of Vestibular Schwannoma? Estimations From a National Registry. Otol. Neurotol. 2016, 37, 1411–1417. [Google Scholar] [CrossRef]
  3. Kshettry, V.R.; Hsieh, J.K.; Ostrom, Q.T.; Kruchko, C.; Barnholtz-Sloan, J.S. Incidence of vestibular schwannomas in the United States. J. Neurooncol. 2015, 124, 223–228. [Google Scholar] [CrossRef]
  4. Matthies, C.; Samii, M. Management of 1000 Vestibular Schwannomas (Acoustic Neuromas): Clinical Presentation. Neurosurgery 1997, 40, 1–10. [Google Scholar] [CrossRef] [PubMed]
  5. Kentala, E.; Pyykkö, I. Clinical picture of vestibular schwannoma. Auris Nasus Larynx 2001, 28, 15–22. [Google Scholar] [CrossRef] [PubMed]
  6. Kanzaki, J.; Tos, M.; Sanna, M.; Moffat, D.A. New and Modified Reporting Systems from the Consensus Meeting on Systems for Reporting Results in Vestibular Schwannoma. Otol. Neurotol. 2003, 24, 642–649. [Google Scholar] [CrossRef] [PubMed]
  7. Goldbrunner, R.; Weller, M.; Regis, J.; Lund-Johansen, M.; Stavrinou, P.; Reuss, D.; Evans, D.G.; Lefranc, F.; Sallabanda, K.; Falini, A.; et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro Oncol. 2020, 22, 31–45. [Google Scholar] [CrossRef] [PubMed]
  8. Robinett, Z.N.; Walz, P.C.; Miles-Markley, B.; Moberly, A.C.; Welling, D.B. Comparison of Long-term Quality-of-Life Outcomes in Vestibular Schwannoma Patients. Otolaryngol. Head Neck Surg. 2014, 150, 1024–1032. [Google Scholar] [CrossRef]
  9. Carlson, M.L.; Tveiten, O.V.; Driscoll, C.L.; Goplen, F.K.; Neff, B.A.; Pollock, B.E.; Tombers, N.M.; Castner, M.L.; Finnkirk, M.K.; Myrseth, E.; et al. Long-term quality of life in patients with vestibular schwannoma: An international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation, and nontumor controls. J. Neurosurg. 2015, 122, 833–842. [Google Scholar] [CrossRef] [PubMed]
  10. Soulier, G.; van Leeuwen, B.M.; Putter, H.; Jansen, J.C.; Malessy, M.J.A.; van Benthem, P.P.G.; van der Mey, A.G.L.; Stiggelbout, A.M. Quality of Life in 807 Patients with Vestibular Schwannoma: Comparing Treatment Modalities. Otolaryngol. Head Neck Surg. 2017, 157, 92–98. [Google Scholar] [CrossRef]
  11. Evans, D.G. Neurofibromatosis 2. In GeneReviews(R); Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Mirzaa, G.M., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993. [Google Scholar]
  12. Plotkin, S.R.; Messiaen, L.; Legius, E.; Pancza, P.; Avery, R.A.; Blakeley, J.O.; Babovic-Vuksanovic, D.; Ferner, R.; Fisher, M.J.; Friedman, J.M.; et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet. Med. 2022, 24, 1967–1977. [Google Scholar] [CrossRef]
  13. Evans, D.G.; Howard, E.; Giblin, C.; Clancy, T.; Spencer, H.; Huson, S.M.; Lalloo, F. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am. J. Med. Genet. A 2010, 152A, 327–332. [Google Scholar] [CrossRef]
  14. Blakeley, J.O.; Evans, D.G.; Adler, J.; Brackmann, D.; Chen, R.; Ferner, R.E.; Hanemann, C.O.; Harris, G.; Huson, S.M.; Jacob, A.; et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am. J. Med. Genet. A 2012, 158A, 24–41. [Google Scholar] [CrossRef]
  15. Hornigold, R.E.; Golding, J.F.; Leschziner, G.; Obholzer, R.; Gleeson, M.J.; Thomas, N.; Walsh, D.; Saeed, S.; Ferner, R.E. The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2. J. Neurol. Surg. Part B Skull Base 2012, 73, 104–111. [Google Scholar] [CrossRef]
  16. Hexter, A.; Jones, A.; Joe, H.; Heap, L.; Smith, M.J.; Wallace, A.J.; Halliday, D.; Parry, A.; Taylor, A.; Raymond, L.; et al. Clinical and molecular predictors of mortality in neurofibromatosis 2: A UK national analysis of 1192 patients. J. Med. Genet. 2015, 52, 699–705. [Google Scholar] [CrossRef] [PubMed]
  17. Ruggieri, M.; Iannetti, P.; Polizzi, A.; La Mantia, I.; Spalice, A.; Giliberto, O.; Platania, N.; Gabriele, A.L.; Albanese, V.; Pavone, L. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: A study of 24 patients. Neuropediatrics 2005, 36, 21–34. [Google Scholar] [CrossRef] [PubMed]
  18. Halliday, D.; Emmanouil, B.; Pretorius, P.; MacKeith, S.; Painter, S.; Tomkins, H.; Evans, D.G.; Parry, A. Genetic Severity Score predicts clinical phenotype in NF2. J. Med. Genet. 2017, 54, 657–664. [Google Scholar] [CrossRef]
  19. Evans, D.G.; Hartley, C.L.; Smith, P.T.; King, A.T.; Bowers, N.L.; Tobi, S.; Wallace, A.J.; Perry, M.; Anup, R.; Lloyd, S.K.W.; et al. Incidence of mosaicism in 1055 de novo NF2 cases: Much higher than previous estimates with high utility of next-generation sequencing. Genet. Med. 2020, 22, 53–59. [Google Scholar] [CrossRef]
  20. de Vries, M.; van der Mey, A.G.L.; Hogendoorn, P.C.W. Tumor Biology of Vestibular Schwannoma: A Review of Experimental Data on the Determinants of Tumor Genesis and Growth Characteristics. Otol. Neurotol. 2015, 36, 1128–1136. [Google Scholar] [CrossRef]
  21. Chiasson-MacKenzie, C.; Vitte, J.; Liu, C.-H.; Wright, E.A.; Flynn, E.A.; Stott, S.L.; Giovannini, M.; McClatchey, A.I. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nat. Commun. 2023, 14, 1559. [Google Scholar] [CrossRef] [PubMed]
  22. Barrett, T.F.; Patel, B.; Khan, S.M.; Mullins, R.D.Z.; Yim, A.K.Y.; Pugazenthi, S.; Mahlokozera, T.; Zipfel, G.J.; Herzog, J.A.; Chicoine, M.R.; et al. Single-cell multi-omic analysis of the vestibular schwannoma ecosystem uncovers a nerve injury-like state. Nat. Commun. 2024, 15, 478. [Google Scholar] [CrossRef]
  23. Woods, R.; Friedman, J.M.; Evans, D.G.R.; Baser, M.E.; Joe, H. Exploring the “two-hit hypothesis” in NF2: Tests of two-hit and three-hit models of vestibular schwannoma development. Genet. Epidemiol. 2003, 24, 265–272. [Google Scholar] [CrossRef]
  24. Carlson, M.L.; Smadbeck, J.B.; Link, M.J.; Klee, E.W.; Vasmatzis, G.; Schimmenti, L.A. Next Generation Sequencing of Sporadic Vestibular Schwannoma: Necessity of Biallelic NF2 Inactivation and Implications of Accessory Non-NF2 Variants. Otol. Neurotol. 2018, 39, e860–e871. [Google Scholar] [CrossRef] [PubMed]
  25. Kehrer-Sawatzki, H.; Farschtschi, S.; Mautner, V.-F.; Cooper, D.N. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum. Genet. 2017, 136, 129–148. [Google Scholar] [CrossRef] [PubMed]
  26. Hadfield, K.D.; Smith, M.J.; Urquhart, J.E.; Wallace, A.J.; Bowers, N.L.; King, A.T.; Rutherford, S.A.; Trump, D.; Newman, W.G.; Evans, D.G. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 2010, 29, 6216–6221. [Google Scholar] [CrossRef]
  27. Hexter, A.T.; Evans, D.G. The Genetics of Vestibular Schwannoma. Curr. Otorhinolaryngol. Rep. 2014, 2, 226–234. [Google Scholar] [CrossRef]
  28. Trofatter, J.A.; MacCollin, M.M.; Rutter, J.L.; Murrell, J.R.; Duyao, M.P.; Parry, D.M.; Eldridge, R.; Kley, N.; Menon, A.G.; Pulaski, K.; et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993, 72, 791–800. [Google Scholar] [CrossRef]
  29. Kim, H.; Kwak, N.-J.; Lee, J.Y.; Choi, B.H.; Lim, Y.; Ko, Y.J.; Kim, Y.-H.; Huh, P.-W.; Lee, K.-H.; Rha, H.K.; et al. Merlin Neutralizes the Inhibitory Effect of Mdm2 on p53. J. Biol. Chem. 2004, 279, 7812–7818. [Google Scholar] [CrossRef] [PubMed]
  30. Jones, G.N.; Tep, C.; Towns, W.H.; Mihai, G.; Tonks, I.D.; Kay, G.F.; Schmalbrock, P.M.; Stemmer-Rachamimov, A.O.; Yoon, S.O.; Kirschner, L.S. Tissue-Specific Ablation of Prkar1a Causes Schwannomas by Suppressing Neurofibromatosis Protein Production. Neoplasia 2008, 10, 1213-IN1219. [Google Scholar] [CrossRef]
  31. Lassaletta, L.; Torres-Martín, M.; Peña-Granero, C.; Roda, J.M.; Santa-Cruz-Ruiz, S.; Castresana, J.S.; Gavilan, J.; Rey, J.A. NF2 Genetic Alterations in Sporadic Vestibular Schwannomas: Clinical Implications. Otol. Neurotol. 2013, 34, 1355–1361. [Google Scholar] [CrossRef] [PubMed]
  32. Piotrowski, A.; Xie, J.; Liu, Y.F.; Poplawski, A.B.; Gomes, A.R.; Madanecki, P.; Fu, C.; Crowley, M.R.; Crossman, D.K.; Armstrong, L.; et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat. Genet. 2014, 46, 182–187. [Google Scholar] [CrossRef]
  33. Agnihotri, S.; Jalali, S.; Wilson, M.R.; Danesh, A.; Li, M.; Klironomos, G.; Krieger, J.R.; Mansouri, A.; Khan, O.; Mamatjan, Y.; et al. The genomic landscape of schwannoma. Nat. Genet. 2016, 48, 1339–1348. [Google Scholar] [CrossRef]
  34. Pathmanaban, O.N.; Sadler, K.V.; Kamaly-Asl, I.D.; King, A.T.; Rutherford, S.A.; Hammerbeck-Ward, C.; McCabe, M.G.; Kilday, J.-P.; Beetz, C.; Poplawski, N.K.; et al. Association of Genetic Predisposition with Solitary Schwannoma or Meningioma in Children and Young Adults. JAMA Neurol. 2017, 74, 1123–1129. [Google Scholar] [CrossRef] [PubMed]
  35. Håvik, A.L.; Bruland, O.; Myrseth, E.; Miletic, H.; Aarhus, M.; Knappskog, P.-M.; Lund-Johansen, M. Genetic landscape of sporadic vestibular schwannoma. J. Neurosurg. 2018, 128, 911–922. [Google Scholar] [CrossRef] [PubMed]
  36. Evans, D.; Ramsden, R.; Gokhale, C.; Bowers, N.; Huson, S.; Wallace, A. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin. Genet. 2007, 71, 354–358. [Google Scholar] [CrossRef] [PubMed]
  37. Mohyuddin, A.; Neary, W.J.; Wallace, A.; Wu, C.L.; Purcell, S.; Reid, H.; Ramsden, R.T.; Read, A.; Black, G.; Evans, D.G.R. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J. Med. Genet. 2002, 39, 315–322. [Google Scholar] [CrossRef] [PubMed]
  38. Evans, D.G.; Wallace, A.J.; Wu, C.L.; Trueman, L.; Ramsden, R.T.; Strachan, T. Somatic Mosaicism: A Common Cause of Classic Disease in Tumor-Prone Syndromes? Lessons from Type 2 Neurofibromatosis. Am. J. Hum. Genet. 1998, 63, 727–736. [Google Scholar] [CrossRef]
  39. Marinelli, J.P.; Lohse, C.M.; Carlson, M.L. Incidence of Vestibular Schwannoma over the Past Half-Century: A Population-Based Study of Olmsted County, Minnesota. Otolaryngol. Head Neck Surg. 2018, 159, 717–723. [Google Scholar] [CrossRef] [PubMed]
  40. Evans, D.G.; Maher, E.R.; Baser, M.E. Age related shift in the mutation spectra of germline and somatic NF2 mutations: Hypothetical role of DNA repair mechanisms. J. Med. Genet. 2005, 42, 630–632. [Google Scholar] [CrossRef]
  41. Evans, D.G.; Raymond, F.L.; Barwell, J.G.; Halliday, D. Genetic testing and screening of individuals at risk of NF2. Clin. Genet. 2012, 82, 416–424. [Google Scholar] [CrossRef] [PubMed]
  42. Halliday, D.; Emmanouil, B.; Evans, D.G.R. Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2-related schwannomatosis. Clin. Genet. 2023, 103, 540–552. [Google Scholar] [CrossRef]
  43. Goodwin, S.; McPherson, J.D.; McCombie, W.R. Coming of age: Ten years of next-generation sequencing technologies. Nat. Rev. Genet. 2016, 17, 333–351. [Google Scholar] [CrossRef]
  44. COREON. Code of Conduct for Health Research. 2022. Available online: https://www.coreon.org/wp-content/uploads/2023/06/Code-of-Conduct-for-Health-Research-2022.pdf (accessed on 2 December 2024).
  45. Leiden University Medical Center. Rare Cancer Panel; Department of Pathology, Leiden University Medical Center: Leiden, The Netherlands, 2023; pp. 1–3. Available online: https://www.palga.nl/media/uploads/pdf/5/8/581_136-rcpl-lumc.pdf (accessed on 2 December 2024).
  46. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–423. [Google Scholar] [CrossRef]
  47. Karbassi, I.; Maston, G.A.; Love, A.; DiVincenzo, C.; Braastad, C.D.; Elzinga, C.D.; Bright, A.R.; Previte, D.; Zhang, K.; Rowland, C.M.; et al. A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders. Hum. Mutat. 2016, 37, 127–134. [Google Scholar] [CrossRef] [PubMed]
  48. Sadler, K.V.; Bowers, N.L.; Hartley, C.; Smith, P.T.; Tobi, S.; Wallace, A.J.; King, A.; Lloyd, S.K.W.; Rutherford, S.; Pathmanaban, O.N.; et al. Sporadic vestibular schwannoma: A molecular testing summary. J. Med. Genet. 2021, 58, 227–233. [Google Scholar] [CrossRef]
  49. Kluwe, L.; Friedrich, R.E.; Hagel, C.; Lindenau, M.; Mautner, V.-F. Mutations and Allelic Loss of the NF2 Gene in Neurofibromatosis 2-Associated Skin Tumors. J. Investig. Dermatol. 2000, 114, 1017–1021. [Google Scholar] [CrossRef] [PubMed]
  50. Teranishi, Y.; Miyawaki, S.; Hongo, H.; Dofuku, S.; Okano, A.; Takayanagi, S.; Ota, T.; Yoshimura, J.; Qu, W.; Mitsui, J.; et al. Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2. J. Med. Genet. 2021, 58, 701–711. [Google Scholar] [CrossRef] [PubMed]
  51. Kluwe, L.; MacCollin, M.; Tatagiba, M.; Thomas, S.; Hazim, W.; Haase, W.; Mautner, V.-F. Phenotypic variability associated with 14 splice-site mutations in the NF2 Gene. Am. J. Med. Genet. 1998, 77, 228–233. [Google Scholar] [CrossRef]
  52. Baser, M.E.; Kuramoto, L.; Woods, R.; Joe, H.; Friedman, J.M.; Wallace, A.J.; Ramsden, R.T.; Olschwang, S.; Bijlsma, E.; Kalamarides, M.; et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J. Med. Genet. 2005, 42, 540–546. [Google Scholar] [CrossRef] [PubMed]
  53. Chen, H.; Zhang, X.; Zhang, Z.; Yang, T.; Wang, Z.; Wu, H. The role of NF2 gene mutations and pathogenesis-related proteins in sporadic vestibular schwannomas in young individuals. Mol. Cell. Biochem. 2014, 392, 145–152. [Google Scholar] [CrossRef] [PubMed]
  54. Sadler, K.V.; Rowlands, C.F.; Smith, P.T.; Hartley, C.L.; Bowers, N.L.; Roberts, N.Y.; Harris, J.L.; Wallace, A.J.; Evans, D.G.; Messiaen, L.M.; et al. Re-evaluation of missense variant classifications in NF2. Hum. Mutat. 2022, 43, 643–654. [Google Scholar] [CrossRef] [PubMed]
  55. Ahronowitz, I.; Xin, W.; Kiely, R.; Sims, K.; MacCollin, M.; Nunes, F.P. Mutational spectrum of the NF2 gene: A meta-analysis of 12 years of research and diagnostic laboratory findings. Hum. Mutat. 2007, 28, 1–12. [Google Scholar] [CrossRef] [PubMed]
  56. Louvrier, C.; Pasmant, E.; Briand-Suleau, A.; Cohen, J.; Nitschké, P.; Nectoux, J.; Orhant, L.; Zordan, C.; Goizet, C.; Goutagny, S.; et al. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro Oncol. 2018, 20, 917–929. [Google Scholar] [CrossRef]
Cancers 17 00393 g001
Figure 1. Multi-hit mechanism for the development of vestibular schwannoma in (a) patients with NF2 (n = 16), (b) young patients with uVS (≤30 years) (n = 36), and (c) older patients with uVS (≥40 years) (n = 41). Legend: patients with NF2 = patients with NF2-related schwannomatosis; uVS = unilateral vestibular schwannoma; and LOH = loss of heterozygosity.
Figure 1. Multi-hit mechanism for the development of vestibular schwannoma in (a) patients with NF2 (n = 16), (b) young patients with uVS (≤30 years) (n = 36), and (c) older patients with uVS (≥40 years) (n = 41). Legend: patients with NF2 = patients with NF2-related schwannomatosis; uVS = unilateral vestibular schwannoma; and LOH = loss of heterozygosity.
Cancers 17 00393 g001
Cancers 17 00393 g002
Figure 2. Total number of mutational events detected in vestibular schwannomas in (a) patients with NF2, (b) young patients with uVS (≤30 years), and (c) older patients with uVS (≥40 years). Legend: NF2 = NF2-related schwannomatosis; and uVS = unilateral vestibular schwannoma.
Figure 2. Total number of mutational events detected in vestibular schwannomas in (a) patients with NF2, (b) young patients with uVS (≤30 years), and (c) older patients with uVS (≥40 years). Legend: NF2 = NF2-related schwannomatosis; and uVS = unilateral vestibular schwannoma.
Cancers 17 00393 g002
Table 1. Demographics and treatment characteristics of the study cohort.
Table 1. Demographics and treatment characteristics of the study cohort.
Patient CharacteristicsPatients with NF2,
n = 16		Patients with uVS ≤ 30 Years, n = 36Patients with uVS ≥ 40 Years, n = 41
Female, n (%)11 (68.8)24 (66.7)20 (48.8)
Age, years, median (range)
Diagnosis33.7 (12.6–61.9) 27.1 (16.7–30.6) 55.5 (40.0–79.5)
Time of treatment35.0 (20.7–62.7)28.0 (17.0–38.4)56.4 (43.7–81.0)
Current54 (25–79)32 (18–44)58 (45–84)
Family history of NF2 or uVS, n (%)1 (6.7)0 (0.0)1 (2.4)
Previous treatment on target tumor, n (%)
Surgical resection2 (12.5)2 (5.6)0 (0.0)
Radiotherapy0 (0.05 (13.9)0 (0.0)
Bevacizumab2 (12.5)n.a.n.a.
Surgical indication, n (%)
Large tumor size10 (71.4)22 (61.1)11 (26.8)
Tumor progression2 (14.3)9 (25.0)23 (56.1)
Symptoms2 (14.3)5 (13.9)7 (17.1)
Legend: NF2 = NF2-related schwannomatosis; n = number of patients; uVS = unilateral vestibular schwannoma; and n.a. = not applicable.
Table 2. Pathogenic germline variants in five patients with NF2-related schwannomatosis.
Table 2. Pathogenic germline variants in five patients with NF2-related schwannomatosis.
No.Age at Pres.ExonDNA SequenceProtein
Sequence		Variant TypeGenetic
Severity
0224.312c.1132G > Tp.Glu378*Nonsense 2B
0416.58c.702dupTp.Gly235Trpfs*Frameshift3
0612.613c.1341-2A > Gp.?Splice site 2A
0730.61c.del22q12.1q12.2p.?Large deletion2A
1527.210c.892C > Tp.Gln298*Nonsense 2B
Legend: No. = patient study number; and Pres. = presentation.
Table 3. Detailed description of nucleotide variants identified in vestibular schwannomas.
Table 3. Detailed description of nucleotide variants identified in vestibular schwannomas.
VariantsPatients with NF2 Patients with uVS
≤30 Years		Patients with uVS
≥40 Years
Gene, n (%)
NF225 (96.2)40 (85.1)48 (92.3)
LZTR101 (2.1)0
SMARCB11 (3.8)3 (6.4)2 (3.8)
Other03 (6.4)2 (3.8)
Type of NF2 variant, n (%)
Substitution14 (56.0)17 (48.6)18 (38.3)
Duplication1 (4.0)2 (5.7)3 (6.4)
Insertion00 1 (2.1)
Deletion8 (32.0)14 (40.0)23 (48.9)
Deletion/insertion1 (4.0)2 (5.7)2 (4.3)
Large deletion1 (4.0)00
Unknown (c.?)041
Effect of NF2 variant, n (%)
Missense 2 (8.3)1 (2.9)2 (4.4)
Splice site 5 (20.8)4 (11.8)6 (13.3)
Frameshift7 (29.2)15 (44.1)23 (51.1)
Nonsense9 (37.5)13 (38.2)12 (26.7)
Deletion1 (4.2)00
Deletion/insertion01 (2.9)1 (2.2)
Silent001 (2.2)
Unknown (p.?)053
Variant location on NF2, n (%)
Exon 11 (4.0)2 (5.1)4 (8.3)
Exons 2–712 (48.0)16 (41.0)22 (45.8)
Exons 8–1311 (44.0)15 (38.5)15 (31.3)
Exons 14–161 (4.0)6 (15.4)7 (14.6)
Pathogenicity classification according to the American College of Medical Genetics and Genomics [47]. Legend: NF2 = NF2-related schwannomatosis; uVS = unilateral vestibular schwannoma; and n = number of cases.
Table 4. Pathogenic tumor variants in patients with NF2-related schwannomatosis with identified germline NF2 variants.
Table 4. Pathogenic tumor variants in patients with NF2-related schwannomatosis with identified germline NF2 variants.
No.First (Germline) NF2 Hit 1Second Hit in TumorThird Hit in Tumor
02c.1132G>, p.Glu378*NF2 (exon 12): c.558_561delGAGA, p.Arg187Leufs*LOH
04c.702dupT, p.Gly235Trpfs*NF2 (exon 12): c.1331C > A, p.Ser444*n.a.
06c.1341-2A > G, p.?LOHn.a.
07c.del22q12.1q12.2, p.?NF2 (exon 7): c.632C > A, p.Ala211Aspn.a.
15c.892C > T, p.Gln298*LOHn.a.
1 Germline details in Table 2. Legend: No. = patient number; LOH = loss of heterozygosity; and n.a. = not applicable.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Douwes, J.P.J.; van Eijk, R.; Maas, S.L.N.; Jansen, J.C.; Aten, E.; Hensen, E.F. Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas. Cancers 2025, 17, 393. https://doi.org/10.3390/cancers17030393

AMA Style

Douwes JPJ, van Eijk R, Maas SLN, Jansen JC, Aten E, Hensen EF. Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas. Cancers. 2025; 17(3):393. https://doi.org/10.3390/cancers17030393

Chicago/Turabian Style

Douwes, Jules P. J., Ronald van Eijk, Sybren L. N. Maas, Jeroen C. Jansen, Emmelien Aten, and Erik F. Hensen. 2025. "Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas" Cancers 17, no. 3: 393. https://doi.org/10.3390/cancers17030393

APA Style

Douwes, J. P. J., van Eijk, R., Maas, S. L. N., Jansen, J. C., Aten, E., & Hensen, E. F. (2025). Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas. Cancers, 17(3), 393. https://doi.org/10.3390/cancers17030393

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop